Inside the Lab Liquid biopsy, Oncology, Genetics and epigenetics, Clinical care, Screening and monitoring, Precision medicine, Omics

Advancing liquid biopsy research using next-generation sequencing: A multi-centre lung cancer cell-free DNA (cfDNA) study

Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up.

01/12/2018

sponsored by Thermo Fisher Scientific

Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up. In this webinar, you will learn:

Why liquid biopsy can represent temporal and spatial heterogeneity in cancer progression
The importance of using next-generation sequencing (NGS) methods in liquid biopsy research studies

View on-demand

Visit our Webinar Hub

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.